◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › V › VRDN

Viridian Therapeutics Inc (VRDN) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-08-30

Viridian Therapeutics Inc (VRDN) operates in the BIOTECHNOLOGY industry and is headquartered in Waltham, United States with about 252 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, VRDN reported $71M in revenue and ($343M) in net income.

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.

Interactive charts & full statements → Open the VRDN valuation workbench →

VRDN Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Total Revenue	$71M	$71M	$0M	$0M	$2M	$3M	$1M	$4M	$8M	$4M	$3M	$3M	$4M	$4M	$4M
Gross Profit	$71M	$71M	$0M	$0M	$2M	$3M	($27M)	$4M	($22M)	($16M)	$1M	$0M	$1M	$2M	$1M
Gross Margin %	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	-2595.6%	100.0%	-262.8%	-390.2%	23.6%	2.6%	24.9%	42.1%	30.9%
Operating Income (EBIT)	($405M)	($363M)	($299M)	($254M)	($134M)	($80M)	($110M)	($42M)	($33M)	($27M)	($13M)	($11M)	($7M)	$0M	($4M)
Operating Margin %	-570.4%	-512.9%	-99018.2%	-81035.0%	-7579.2%	-2690.8%	-10512.4%	-941.0%	-394.5%	-662.8%	-374.8%	-440.8%	-159.0%	-4.5%	-91.4%
Net Income	($387M)	($343M)	($270M)	($238M)	($130M)	($79M)	($111M)	($42M)	($33M)	($27M)	($13M)	($11M)	($8M)	($2M)	($7M)
Net Margin %	-545.1%	-483.6%	-89387.1%	-75711.5%	-7329.2%	-2680.2%	-10544.3%	-938.6%	-390.0%	-662.3%	-379.8%	-446.3%	-182.6%	-50.0%	-163.7%
EBITDA	($368M)	($337M)	($266M)	($235M)	($129M)	($79M)	($40M)	($41M)	($32M)	($26M)	($13M)	($11M)	($7M)	$0M	($4M)
Earnings Per Share (EPS)	$-4.05	$-4.04	$-3.98	$-5.31	$-4.05	$-6.66	$-31.13	$-20.04	$-16.57	$-20.66	$-17.57	$-11.00	$-52.46	$-11.48	$-38.75
Shares Outstanding (M)	108M	85M	68M	45M	32M	12M	4M	2M	2M	1M	1M	1M	0M	0M	0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VRDN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$0M	$0M	$0M	$71M	$0M	$0M	$0M	$0M
Gross Profit	$0M	$0M	$0M	$71M	$0M	$0M	$0M	$0M
Gross Margin %	100.0%	100.0%	-142.4%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	($126M)	($116M)	($123M)	($40M)	($107M)	($94M)	($87M)	($83M)
Operating Margin %	-44460.6%	-82389.4%	-92991.7%	-56.7%	-142356.0%	-130369.4%	-121488.9%	-97069.8%
Net Income	($127M)	($105M)	($120M)	($35M)	($101M)	($87M)	($80M)	($77M)
Net Margin %	-44760.2%	-74397.9%	-91178.0%	-49.0%	-134313.3%	-120711.1%	-110729.2%	-89173.3%
EBITDA	($119M)	($101M)	($114M)	($34M)	($100M)	($86M)	($79M)	($76M)
Earnings Per Share (EPS)	$-1.18	$-1.03	$-1.42	$-0.42	$-1.23	$-1.07	$-1.00	$-1.15
Shares Outstanding (M)	108M	102M	85M	82M	82M	81M	80M	66M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VRDN Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Cash from Operations (CFO)	($334M)	($276M)	($232M)	($184M)	($94M)	($55M)	($30M)	($36M)	($27M)	($28M)	($7M)	($7M)	($2M)	($1M)	($6M)
Capital Expenditures (CapEx)	$1M	$0M	$1M	$1M	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($336M)	($277M)	($233M)	($185M)	($95M)	($55M)	($30M)	($36M)	($27M)	($28M)	($7M)	($7M)	($2M)	($1M)	($6M)
FCF Margin %	-473.2%	-390.8%	-77096.0%	-58938.9%	-5340.6%	-1853.5%	-2840.1%	-810.1%	-325.4%	-709.8%	-216.8%	-276.6%	-57.4%	-27.2%	-143.7%
Dividends Paid	—	—	—	$14M	—	—	$0M	—	—	—	—	—	—	$0M	$1M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VRDN Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($105M)	($120M)	($24M)	($85M)	($75M)	($93M)	($73M)	($68M)
Capital Expenditures (CapEx)	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($107M)	($120M)	($24M)	($85M)	($75M)	($93M)	($73M)	($68M)
FCF Margin %	-37545.8%	-84877.3%	-18177.3%	-120.1%	-100553.3%	-128804.2%	-102008.3%	-79068.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VRDN Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Total Assets	$1.1B	$899M	$742M	$490M	$435M	$204M	$131M	$30M	$66M	$52M	$4M	$13M	$8M	$4M	$3M
Cash & Cash Equivalents	$165M	$212M	$100M	$103M	$156M	$42M	$46M	$25M	$33M	$47M	$3M	$11M	$5M	$0M	$0M
Total Liabilities	$435M	$177M	$71M	$48M	$40M	$16M	$11M	$15M	$15M	$14M	$5M	$2M	$2M	$2M	$24M
Total Debt (Short + Long-Term)	$243M	$51M	$21M	$21M	$5M	$1M	$0M	$8M	$10M	$10M	$1M	$1M	$0M	$1M	$23M
Total Shareholders' Equity	$662M	$722M	$672M	$442M	$395M	$188M	$120M	$16M	$51M	$39M	$0M	$10M	$6M	$2M	($21M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VRDN viewer.

Other Companies in BIOTECHNOLOGY

BRVE · Braveheart Bio, Inc. Common Stock — $3 billion
MRVI · Maravai Lifesciences Holdings Inc — $3 billion
BEAM · Beam Therapeutics Inc — $3 billion
PHVS · Pharvaris BV — $3 billion
MLYS · Mineralys Therapeutics, Inc. Common Stock — $2 billion
VERA · Vera Therapeutics Inc — $2 billion
HRMY · Harmony Biosciences Holdings — $2 billion
SLS · Sellas Life Sciences Group Inc — $2 billion

← VRCA All “V” companies VRDS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.